Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Loris R. Lopetuso, Marco Napoli, Gianenrico Rizzatti & Antonio Gasbarrini. (2018) The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 27:6, pages 543-551.
Read now
Read now
William Chamberlin, Thomas J Borody & Jordana Campbell. (2011) Primary treatment of Crohn’s disease: combined antibiotics taking center stage. Expert Review of Clinical Immunology 7:6, pages 751-760.
Read now
Read now
John K Triantafillidis, Emmanuel Merikas & Filippos Georgopoulos. (2011) Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Design, Development and Therapy 5, pages 185-210.
Read now
Read now
Ulrike Strauch & Jürgen Schölmerich. (2010) Emerging drugs to treat Crohn's disease. Expert Opinion on Emerging Drugs 15:2, pages 309-322.
Read now
Read now
Hoonmo L Koo, Herbert L DuPont & David B Huang. (2009) The role of rifaximin in the treatment and chemoprophylaxis of travelers’ diarrhea. Therapeutics and Clinical Risk Management 5, pages 841-848.
Read now
Read now
Veronica Ojetti, Ernesto Cristiano Lauritano, Federico Barbaro, Alessio Migneco, Maria Elena Ainora, Luigi Fontana, Maurizio Gabrielli & Antonio Gasbarrini. (2009) Rifaximin pharmacology and clinical implications. Expert Opinion on Drug Metabolism & Toxicology 5:6, pages 675-682.
Read now
Read now
Xiaochao Ma, Jeffrey R Idle & Frank J Gonzalez. (2008) The pregnane X receptor: from bench to bedside. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 895-908.
Read now
Read now
Brian W Behm & Stephen J Bickston. (2006) Medical management of Crohn's disease: current therapy and recent advances. Expert Review of Clinical Immunology 2:1, pages 109-120.
Read now
Read now
Articles from other publishers (46)
Walaa Abdelaty Shaheen, Mohammed Nabil Quraishi & Tariq H Iqbal. (2022) Gut microbiome and autoimmune disorders. Clinical and Experimental Immunology 209:2, pages 161-174.
Crossref
Crossref
Carlos Daniel Bautista-Olivier & Guillermo Elizondo. (2022) PXR as the tipping point between innate immune response, microbial infections, and drug metabolism. Biochemical Pharmacology 202, pages 115147.
Crossref
Crossref
E. Yu. Plotnikova. (2021) Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases. Meditsinskiy sovet = Medical Council:5, pages 167-174.
Crossref
Crossref
Scott D. Lee, Anand Singla, Stephen J. Rulyak & Kindra Clark‐Snustad. (2020) Double‐blind, randomised, placebo‐controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn’s disease. GastroHep 2:5, pages 185-192.
Crossref
Crossref
Katharine G. HarrisEugene B. Chang. (2018) The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease. Clinical Science 132:18, pages 2013-2028.
Crossref
Crossref
Oren Ledder & Dan Turner. (2018) Antibiotics in IBD: Still a Role in the Biological Era?. Inflammatory Bowel Diseases 24:8, pages 1676-1688.
Crossref
Crossref
Alyssa M. Parian, Gerard E. Mullin, Jost Langhorst & Amy C. Brown. 2018. Integrative Medicine. Integrative Medicine
501
516.e8
.
Danilo Pagliari, Giovanni Gambassi, Ciriaco A. Piccirillo & Rossella Cianci. (2017) The Intricate Link among Gut “Immunological Niche,” Microbiota, and Xenobiotics in Intestinal Pathology. Mediators of Inflammation 2017, pages 1-12.
Crossref
Crossref
Lindsey Albenberg, Howard Kader & Adam Paul. 2017. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
325
331
.
Alessandro Menozzi, Manuel Dall’Aglio, Fausto Quintavalla, Luca Dallavalle, Valentina Meucci & Simone Bertini. (2016) Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial. BMC Veterinary Research 12:1.
Crossref
Crossref
Teresa Graziano, Angela Amoruso, Stefania Nicola, Francesca Deidda, Serena Allesina, Marco Pane, Pietro Piffanelli, Francesco Strozzi, Luca Mogna & Mario Del Piano. (2016) The Possible Innovative Use of Bifidobacterium longum W11 in Association With Rifaximin. Journal of Clinical Gastroenterology 50:Supplement 2, pages S153-S156.
Crossref
Crossref
D Weber, P J Oefner, K Dettmer, A Hiergeist, J Koestler, A Gessner, M Weber, F Stämmler, J Hahn, D Wolff, W Herr & E Holler. (2016) Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplantation 51:8, pages 1087-1092.
Crossref
Crossref
Rani H Shayto, Rachel Abou Mrad & Ala I Sharara. (2016) Use of rifaximin in gastrointestinal and liver diseases. World Journal of Gastroenterology 22:29, pages 6638.
Crossref
Crossref
Francesca Romana Ponziani, Franco Scaldaferri, Valentina Petito, Francesco Paroni Sterbini, Silvia Pecere, Loris R. Lopetuso, Alessandra Palladini, Viviana Gerardi, Luca Masucci, Maurizio Pompili, Giovanni Cammarota, Maurizio Sanguinetti & Antonio Gasbarrini. (2016) The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Digestive Diseases 34:3, pages 269-278.
Crossref
Crossref
Herbert L. DuPont. (2015) Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. Mayo Clinic Proceedings 90:8, pages 1116-1124.
Crossref
Crossref
Parth J Parekh, Luis A Balart & David A Johnson. (2015) The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. Clinical and Translational Gastroenterology 6:6, pages e91.
Crossref
Crossref
Giovanni Cammarota, Gianluca Ianiro, Rossella Cianci, Stefano Bibbò, Antonio Gasbarrini & Diego Currò. (2015) The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. Pharmacology & Therapeutics 149, pages 191-212.
Crossref
Crossref
Francesca Romana Ponziani. (2015) Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World Journal of Gastroenterology 21:43, pages 12322.
Crossref
Crossref
Roberto Lorenzetti & Cosimo Prantera. (2013) Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results. Clinical Investigation 3:12, pages 1187-1193.
Crossref
Crossref
Svend T. Rietdijk & Geert R. D'Haens. (2013) Recent developments in the treatment of inflammatory bowel disease. Journal of Digestive Diseases 14:6, pages 282-287.
Crossref
Crossref
Howard Kader, Douglas Jacobstein & Adam Paul. 2013. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
289
294
.
Belgin Dogan, Ellen Scherl, Brian Bosworth, Rhonda Yantiss, Craig Altier, Patrick L. McDonough, Zhi-Dong Jiang, Herbert L. DuPont, Philippe Garneau, Josee Harel, Mark Rishniw & Kenneth W. Simpson. (2013) Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohnʼs Disease. Inflammatory Bowel Diseases 19:1, pages 141-150.
Crossref
Crossref
Marta Dworakowska-Kicińska & Mieczysława Czerwionka-Szaflars. (2012) Zastosowanie rifaksyminy w medycynie wieku rozwojowego. Pediatria Polska 87:1, pages 8-13.
Crossref
Crossref
Jürgen Glas, Julia Seiderer, Daniel Fischer, Barbara Tengler, Simone Pfennig, Martin Wetzke, Florian Beigel, Torsten Olszak, Maria Weidinger, Burkhard Göke, Thomas Ochsenkühn, Matthias Folwaczny, Bertram Müller-Myhsok, Julia Diegelmann, Darina Czamara & Stephan Brand. (2011) Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease. Inflammatory Bowel Diseases 17:9, pages 1917-1924.
Crossref
Crossref
Bruce E. Sands. 2011. The ASCRS Textbook of Colon and Rectal Surgery. The ASCRS Textbook of Colon and Rectal Surgery
463
478
.
Simone Maccaferri, Beatrice Vitali, Annett Klinder, Sofia Kolida, Maurice Ndagijimana, Luca Laghi, Fiorella Calanni, Patrizia Brigidi, Glenn R. Gibson & Adele Costabile. (2010) Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. Journal of Antimicrobial Chemotherapy 65:12, pages 2556-2565.
Crossref
Crossref
A. S. Day & R. B. Gearry. (2010) Rifaximin and Crohn’s Disease: A New Solution to an Old Problem?. Digestive Diseases and Sciences 55:4, pages 877-879.
Crossref
Crossref
Ira Shafran & Patricia Burgunder. (2010) Adjunctive Antibiotic Therapy with Rifaximin May Help Reduce Crohn’s Disease Activity. Digestive Diseases and Sciences 55:4, pages 1079-1084.
Crossref
Crossref
Leonard B. Weinstock, Brian P. Bosworth, Ellen J. Scherl, Ellen Li, Ugonna Iroku, Melissa A. Munsell, Gerald E. Mullen & Arthur S. Walters. (2010) Crohnʼs disease is associated with restless legs syndrome. Inflammatory Bowel Diseases 16:2, pages 275-279.
Crossref
Crossref
Hoonmo L Koo & Herbert L DuPont. (2010) Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Current Opinion in Gastroenterology 26:1, pages 17-25.
Crossref
Crossref
Pramodha Muniyappa, Reema Gulati, Franziska Mohr & Vera Hupertz. (2009) Use and Safety of Rifaximin in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 49:4, pages 400-404.
Crossref
Crossref
Alessandra di Masi, Elisabetta De Marinis, Paolo Ascenzi & Maria Marino. (2009) Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Molecular Aspects of Medicine 30:5, pages 297-343.
Crossref
Crossref
Mario Guslandi. (2009)
Campylobacter concisus
: a New Character in the Crohn's Disease Story?
. Journal of Clinical Microbiology 47:5, pages 1614-1615.
Crossref
Crossref
Gary R Lichtenstein, Stephen B Hanauer & William J Sandborn. (2009) Management of Crohn's Disease in Adults. The American Journal of Gastroenterology 104:2, pages 465-483.
Crossref
Crossref
. (2008) Rifaximin for the Treatment of Newly Diagnosed Crohn's Disease: A Case Series. The American Journal of Gastroenterology 103:8, pages 2158-2160.
Crossref
Crossref
. (2008) Rifaximin for the Treatment of Newly Diagnosed Crohn's Disease: A Case Series. The American Journal of Gastroenterology, pages ???-???.
Crossref
Crossref
Gert De Hertogh. (2008) Evidence for the involvement of infectious agents in the pathogenesis of Crohn’s disease. World Journal of Gastroenterology 14:06, pages 845.
Crossref
Crossref
Douglas Jacobstein & Howard Kader. 2008. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
329
336
.
R. Balfour Sartor & Marcus Muehlbauer. (2007) Microbial host interactions in IBD: Implications for pathogenesis and therapy. Current Gastroenterology Reports 9:6, pages 497-507.
Crossref
Crossref
Xiaochao Ma, Yatrik M. Shah, Grace L. Guo, Ting Wang, Kristopher W. Krausz, Jeffrey R. Idle & Frank J. Gonzalez. (2007) Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator. Journal of Pharmacology and Experimental Therapeutics 322:1, pages 391-398.
Crossref
Crossref
Ellen J. Scherl. (2007) Bacteria, bugs, and BID rifaximin for Crohnʼs disease. Inflammatory Bowel Diseases 13:6, pages 800-801.
Crossref
Crossref
Sheila M Wilhelm, Jason D Taylor, Lisa L Osiecki & Pramodini B Kale-Pradhan. (2016) Novel Therapies for Crohn's Disease: Focus on Immunomodulators and Antibiotics. Annals of Pharmacotherapy 40:10, pages 1804-1813.
Crossref
Crossref
Molly Perencevich & Robert Burakoff. (2006) Use of antibiotics in the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases 12:7, pages 651-664.
Crossref
Crossref
C. PRANTERA, H. LOCHS, M. CAMPIERI, M. L. SCRIBANO, G. C. STURNIOLO, F. CASTIGLIONE & M. COTTONE. (2006) Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Alimentary Pharmacology and Therapeutics 23:8, pages 1117-1125.
Crossref
Crossref
Mario Guslandi, Maria Chiara Petrone & Pier Alberto Testoni. (2006) Rifaximin for active ulcerative colitis. Inflammatory Bowel Diseases 12:4, pages 335.
Crossref
Crossref
Paolo Gionchetti, Fernando Rizzello, Karen M. Lammers, Claudia Morselli, Rosy Tambasco & Massimo Campieri. (2006) Antimicrobials in the Management of Inflammatory Bowel Disease. Digestion 73:1, pages 77-85.
Crossref
Crossref